This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryInterferon beta-1a treatment reduced the rate at which high-risk individuals develop clinically definite multiple sclerosis by 44% compared to placebo, according to a study published in the Sept. 28 New England Journal of Medicine. The 383-patient study also showed that 20 mcg Avonex injected intramuscularly once a week for up to three years had "a highly significant positive impact in reducing the rate at which patients developed brain abnormalities, or lesions, visible on MRI scans" compared to placebo, according to the company. Biogen plans to apply for an expanded label to reflect this early treatment regime
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.